The regression of a canine Langerhans cell tumour is associated with increased expression of IL-2, TNF-α, IFN-γ and iNOS mRNA

Immunology

Volumn 118, Issue 4, 2006, Pages 472-482

  Kaim, Ute ^a   Moritz, Andreas ^b   Failing, Klaus ^b   Baumgärtner, Wolfgang ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Canine cutaneous histiocytoma; CD4+ T cells; CD8+ T cells; Macrophages; Th1 cytokines

Indexed keywords

CD3 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 2; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HISTIOCYTE; HISTIOCYTOMA; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LANGERHANS CELL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MALE; MOLECULAR DYNAMICS; NICK END LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION; UPREGULATION;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; CELL COUNT; CYTOKINES; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTIOCYTOMA, BENIGN FIBROUS; IN SITU NICK-END LABELING; INTERFERON TYPE II; INTERLEUKIN-2; LANGERHANS CELLS; MACROPHAGES; MALE; NEOPLASM REGRESSION, SPONTANEOUS; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746216341     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02394.x     Document Type: Article

References (42)

1. Scott DW, Miller WH Jr, Griffin CE. Neoplastic and non-neoplastic tumours. In: Muller GH, ed. Muller and Kirk's Small Animal Dermatology, 6th edn. Philadelphia, WB Saunders Company 2001:1236-414.
2. Taylor DON, Dorn CR, Luis OH. Morphologic and biologic characteristics of the canine cutaneous histiocytoma. Cancer Res 1969; 29:83-92.
3. Hendrick MJ, Mahaffey EA, Moore FM, Vos JH, Walder EJ. Histiocytic tumours. In: Schulman Fy, ed. WHO International Histological Classification of Mesenchymal Tumours of Skin and Soft Tissues of Domestic Animals. Second series, Vol. II. Washington, DC: Armed Forces Institute of Pathology, 1998:29-31.
4. Moore PF, Schrenzel MD, Affolter VK, Olivry T, Naydan D. Canine cutaneous histiocytoma is an epidermotropic Langerhans cell histiocytosis that expresses CD1 and specific beta 2-integrin molecules. Am J Pathol 1996; 148:1699-708.
5. Cockerell GL, Slauson DO. Patterns of lymphoid infiltrate in the canine cutaneous histiocytoma. J Comp Pathol 1979; 89:193-203.
6. Marchal T, Dezutter-Dambuyant C, Fournel C, Magnol JP, Schmitt D. Electron microscopic study on canine cutaneous histioytoma: a benign Langerhans cell tumour. In: Banchereau J, Scmitt D, eds. Dendritic Cells in Fundamental and Clinical Immunology. Series 2. Advances in Experimental Medicine and Biology 378. New York: Plenum Press, 1995:549-51.
7. Baines SJ, Bujdoso R, Blacklaws BA, McInnes E, Moore PF, McConnel IM. Maturation stages of dendritic cells in canine cutaneous histioytoma. Vet Dermatol 2000; 11 (Suppl. 1):9-10.
8. Kipar A, Baumgärtner W, Kremmer E, Frese K, Weiss E. Expression of major histocompatibility complex class II antigen in neoplastic cells of canine cutaneous histiocytoma. Vet Immunol Immunopathol 1998; 62:1-13.
9. Wünschmann A, Alldinger S, Kremmer E, Baumgärtner W. Identification of CD4+ and CD8+ T-cell subsets and B cells in the brain of dogs with spontaneous acute, subacute, and chronic-demyelinating distemper encephalitis. Vet Immunol Immunopathol 1999; 67:101-16.
10. Markus S, Failing K, Baumgärtner W. Increased expression of pro-inflammmatory cytokines and lack of up-regulation of antiinflammatory cytokines in early distemper CNS lesions. J Neuroimmunol 2002; 125:30-41.
11. Flavell DJ, Jones DB, Wright DH. Identification of tissue histiocytes on paraffin sections by a new monoclonal antibody. J Histochem Cytochem 1987; 35:1217-26.
12. Perez J, Day MJ, Mozos E. Immunohistochemical study of the local inflammatory infiltrate in spontaneous canine transmissible veneral tumour at different stages of growth. Vet Immunol Immunopathol 1998; 64:133-47.
13. Gröne A, Frisk AL, Baumgärtner W. Cytokine mRNA expression in whole blood samples from dogs with natural canine distemper virus infection. Vet Immunol Immunopathol 1998; 65:11-27.
14. Dixon WJ, ed. BMDP Statistical Software Manual, vols 1 and 3. Berkeley, LA/Oxford: University of California Press, 1993.
15. Bennett SRM, Carbone FR, Karamalis F, Miller JFAP, Heath WR. Induction of a CD8+ cytotoxic T-lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997; 186:65-70.
16. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class 1-restricted tumour antigens. Science 1994; 264:961-5.
17. Bennett SRM, Carbone FR, Karamalis F, Flavell RA, Miller JFAP, Heath WR. Help for cytotoxic T cell response is mediated by CD40 signaling. Nature 1998; 393:478-80.
18. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4+ T-cells in the antitumour immune response. J Exp Med 1998; 188:2357-68.
19. Bingle L, Brown NJ, Lewis CE. The role of macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196:254-65.
20. Jenkins DC, Charles IG, Thomsen LL et al. The role of nitric oxide in tumour growth. Proc Natl Acad Sci USA 1995; 92:4392-6.
21. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7.
22. Soini Y, Pääkkö P, Letho V-P. Histopathological evaluation of apoptosis in cancer. Am J Pathol 1998; 153:1041-53.
23. Petersen BL, Rengtved P, Bank MI, Carstens H. High expression of markers of apoptosis in Langerhans cell histiocytosis. Histopathohgy 2003; 42:186-93.
24. Rodella L, Rezzani R, Zauli G, Mariani AR, Rizzoli R, Vitale M. Apoptosis induced by NK cells is modulated by the NK-active cytokines IL-2 and IL-12. Int Immunol 1997; 10:719-25.
25. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001; 250:462-75.
26. Fehinger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002; 13:169-83.
27. Ikeda H, Old LJ, Schreiber RD. The roles of IFNγ in protection against tumour development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13:95-109.
28. Fujiwara H, Clark SC, Hamaoka T. Cellular and molecular mechanisms underlying IL-12 induced tumour regression. Ann NY Acad Sci 1996; 795:294-309.
29. Fujiwara H, Hamaoka T. The anti-tumour effects of IL-12 involve enhanced IFN-γ production by anti-tumour T cells, their accumulation to tumour sites and in situ IFN-γ production. Leukemia 1997; 11 (Suppl. 3):570-1.
30. Le J, Vilcek J. Tumour necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 1987; 56:234-48.
31. Balkwill F. Tumour necrosis factor or tumour promoting factor? Cytokine Growth Factor Rev 2002; 13:135-41.
32. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
33. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumour immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13:155-68.
34. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004; 202:96-104.
35. Lo CH, Lee S-H, Wu PY et al. Antitumour and antimetastatic activity of IL-23. J Immunol 2003; 171:600-7.
36. Fiorentino DF, Zlotnik A, Vieira P, Mosman TR, Howard M, Moore KW, O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th 1 cells. J Immunol 1991; 146:3444-51.
37. Fontana A, Constam DB, Frei K, Malipiero U, Pfister HW. Modulation of the immune response by transforming growth factor beta. Int Arch Allergy Immunol 1992; 99:1-7.
38. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, Uyemura K. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local immune response. J Immunol 1995; 155:2240-7.
39. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumour microenvironment. J Immunother 2001; 24:392-407.
40. Levitsky HI. Tumours derived from antigen presenting cells. Semin Immunol 1996; 8:281-7.
41. Drake CG, Pardoll DM. Tumour immunology - towards a paradigm of reciprocal research. Semin Cancer Biol 2002; 12:73-80.
42. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45.